ARC1905 ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 301 | Macular dystrophy | 5 |
301. Macular dystrophy
Clinical trials : 45 / Drugs : 46 - (DrugBank : 12) / Drug target genes : 9 - Drug target pathways : 67
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2017-004783-35-DE (EUCTR) | 10/07/2018 | 23/01/2018 | A Clinical Trial to Assess the Safety and Efficacy of Intravitreous Administration of Zimura in Subjects with Autosomal Recessive Stargardt Disease | A Phase 2b Randomized, Double-masked, Controlled Trial to Establish the Safety and Efficacy of Zimura™ (Complement C5 Inhibitor) Compared to Sham in Subjects with Autosomal Recessive Stargardt Disease | Autosomal Recessive Stargardt Disease MedDRA version: 20.1;Level: PT;Classification code 10062766;Term: Stargardt's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Eye Diseases [C11] | Product Name: Zimura Product Code: ARC1905 INN or Proposed INN: avacincaptad pegol Other descriptive name: ARC1905 20 MG/ML | IVERIC bio | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 70 | Phase 2 | United States;France;Hungary;Canada;Spain;Israel;Germany;United Kingdom;Italy | ||
| 2 | EUCTR2017-004783-35-IT (EUCTR) | 05/06/2018 | 25/01/2021 | A Clinical Trial to Assess the Safety and Efficacy of Intravitreous Administration of Zimura in Subjects with Autosomal Recessive Stargardt Disease | A Phase 2b Randomized, Double-masked, Controlled Trial to Establish the Safety and Efficacy of Zimura™ (Complement C5 Inhibitor) Compared to Sham in Subjects with Autosomal Recessive Stargardt Disease - A Clinical Trial to Assess the Safety and Efficacy of Intravitreous Administration of Zimura in Subj | Autosomal Recessive Stargardt Disease MedDRA version: 20.1;Level: PT;Classification code 10062766;Term: Stargardt's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Eye Diseases [C11] | Product Name: Zimura Product Code: [ARC1905] INN or Proposed INN: avacincaptad pegol Other descriptive name: ARC1905 | IVERIC bio, Inc. | NULL | Not Recruiting | Female: yes Male: yes | 120 | Phase 2 | France;United States;Hungary;Canada;Spain;Israel;Germany;United Kingdom;Italy | ||
| 3 | EUCTR2017-004783-35-GB (EUCTR) | 29/05/2018 | 26/01/2018 | A Clinical Trial to Assess the Safety and Efficacy of Intravitreous Administration of Zimura in Subjects with Autosomal Recessive Stargardt Disease | A Phase 2b Randomized, Double-masked, Controlled Trial to Establish the Safety and Efficacy of Zimura™ (Complement C5 Inhibitor) Compared to Sham in Subjects with Autosomal Recessive Stargardt Disease | Autosomal Recessive Stargardt Disease MedDRA version: 20.1;Level: PT;Classification code 10062766;Term: Stargardt's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Eye Diseases [C11] | Product Name: Zimura Product Code: ARC1905 INN or Proposed INN: avacincaptad pegol Other descriptive name: ARC1905 20 MG/ML | IVERIC bio | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 70 | Phase 2 | United States;France;Hungary;Canada;Spain;Israel;Germany;Italy;United Kingdom | ||
| 4 | EUCTR2017-004783-35-ES (EUCTR) | 09/04/2018 | 02/02/2018 | A Clinical Trial to Assess the Safety and Efficacy of Intravitreous Administration of Zimura in Subjects with Autosomal Recessive Stargardt Disease | A Phase 2b Randomized, Double-masked, Controlled Trial to Establish the Safety and Efficacy of Zimura™ (Complement C5 Inhibitor) Compared to Sham in Subjects with Autosomal Recessive Stargardt Disease | Autosomal Recessive Stargardt Disease MedDRA version: 20.1;Level: PT;Classification code 10062766;Term: Stargardt's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Eye Diseases [C11] | Product Name: Zimura Product Code: ARC1905 INN or Proposed INN: avacincaptad pegol Other descriptive name: ARC1905 20 MG/ML | OPHTHOTECH CORPORATION | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 120 | Phase 2 | France;United States;Hungary;Canada;Spain;Israel;Germany;Italy;United Kingdom | ||
| 5 | EUCTR2017-004783-35-HU (EUCTR) | 21/03/2018 | 01/02/2018 | A Clinical Trial to Assess the Safety and Efficacy of Intravitreous Administration of Zimura in Subjects with Autosomal Recessive Stargardt Disease | A Phase 2b Randomized, Double-masked, Controlled Trial to Establish the Safety and Efficacy of Zimura™ (Complement C5 Inhibitor) Compared to Sham in Subjects with Autosomal Recessive Stargardt Disease | Autosomal Recessive Stargardt Disease MedDRA version: 20.1;Level: PT;Classification code 10062766;Term: Stargardt's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Eye Diseases [C11] | Product Name: Zimura Product Code: ARC1905 INN or Proposed INN: avacincaptad pegol Other descriptive name: ARC1905 20 MG/ML | IVERIC bio | NULL | Not Recruiting | Female: yes Male: yes | 70 | Phase 2 | United States;France;Hungary;Canada;Spain;Israel;Germany;United Kingdom;Italy |